aurora inhibitor 1

Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).

Aurora A inhibitor 1 是有效的、选择性的 Aurora A 抑制剂。 Aurora A 与多种组织学起源的癌症有关，而且在过度表达时可能表现出致癌活性。Aurora A inhibitor 1 表现出潜力进行 Aurora A 介导的癌症疾病的研究。

Palmatine chloride 是口服具有活力的不可逆 IDO-1抑制剂。它能够减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，并改善 DSS 诱发的结肠炎。

Palmatine (Burasaine) 是口服具有活力的、不可逆IDO-1抑制剂。它可以减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，从而改善DSS (Dextran Sulphate Sodium Salt) 诱发的结肠炎。它有用于结肠炎的研究潜力。

AT9283 (J-504568) 是一种多靶点激酶抑制剂，抑制多种实体瘤在体内外的生长和存活，有效抑制Aurora A B，JAK2 3，Abl (T315I)，和Flt3，IC50值范围为 1-30 nM。

TAK-285 是一种新型 HER2 和 EGFR(HER1) 双重抑制剂，IC50 分别为 17 和 23 nM。它可穿过血脑屏障，有抗肿瘤活性，对 HER1 2 的选择性是 HER4 的 10 倍以上。

FAK aurora Kinase-IN-1，作为FAK与极光激酶抑制剂，其IC50为6.61 nM和0.91 nM，分别针对FAK和极光激酶。此化合物显示了其抗癌潜力（WO2018019252A1; compound 11）。

JAB-2485是一种有效的选择性极光激酶A (AURKA) 抑制剂，IC50值为0.33 nM，对AURKA的选择性比AURKB高约1700倍，诱导细胞周期停滞和细胞凋亡，可用于癌症研究。

Ilorasertib (ABT-348) 是一种 ATP 竞争性多靶点激酶抑制剂，可抑制 Aurora A、Aurora B 和Aurora C，IC50值为120 nM、7 nM 和1 nM。它还抑制 RET 酪氨酸激酶、PDGFRβ 和 Flt1，IC50为7 nM、3 nM 和 32 nM。

GSK2646264 (Compound 44) is a highly effective and specific inhibitor of spleen tyrosine kinase (SYK) with a pIC50 of 7.1. In addition to targeting SYK, GSK2646264 also inhibits several other kinases, including LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B, and Aurora A, with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3, respectively. Notably, GSK2646264 demonstrates skin penetrability, reaching both the epidermis and dermis [1].

Aurora kinaseinhibitor-11 (compound 25) 作为极光激酶 (Aurora Kinase) 的抑制剂，显现出其IC50为0.14 μM的强效性能。此外，该化合物还表现出抗癌活性。

AKI603 是一种极光激酶 A 抑制剂，IC50值为 12.3 nM。它对白血病细胞具有很强的抗增殖活性，可用于克服白血病中 BCR-ABL-T315I 耐药性突变。

Aurora kinase inhibitor-3 (Aurora Kinase Inhibitor III) 是一种有效的，选择性 Aurora A 激酶抑制剂，IC50为 42 nM。

CCT129202 是一种 ATP 竞争性泛极光激酶抑制剂，作用于 Aurora A、Aurora B 和 Aurora C，IC50 分别为 0.042 μM、0.198 μM 和 0.227 μM。

XMD-12, also known as DUN57447, Aurora inhibitor (compound 1) or Aurora-IN-1, is an Auroro inhibitor, which targets Aurora A B C. (5.6 18.4 24.6 nM).

SAR156497 is an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy with IC50 = 0.5 nM (Aurora A); 1 nM (Aurora B incenp); 3 nM (Aurora C incenp) respectively SAR156497 combines high in vitro potency with satisfactory metabolic stability and limited CYP 3A4 and PDE3 inhibition. In vitro, SAR156497 displayed high antiproliferative activity on a large panel of tumor cell lines without correlation with any particular genetic signature or Aurora kinases expression. It induced significant modulation of Aurora A and Aurora B biomarkers (p-Aurora A and pHH3, respectively) and cell polyploidy, as expected from Aurora A B inhibitors.

Aurora B inhibitor 1 是一种 Aurora B (Aurora-1) 抑制剂（Ki <0.010 uM），具有潜在的抗癌活性，可用于研究癌症。

AURKA against 1(compound Ac13) 作为针对Aurora激酶(AURKA)的抑制剂，其IC50值低于0.5 nM，专门靶向K162位点的内源性赖氨酸乙酰化，并展示了阻断肿瘤细胞增殖的能力。在HCT116细胞中转染了SIRT3后，AURKA against 1诱导的K162位点乙酰化的AURKA激酶活性能够被逆转。

6K465是一种嘧啶基Aurora A (AURKA)抑制剂，能够降低c-MYC和N-MYC癌蛋白水平，具有抗癌活性。

AZD 1152 is an orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50= 0.36 nM).1AZD 1152 is converted to AZD 1152-HQPA in plasma. Inhibition of Aurora B results in disruption of spindle checkpoint functions and chromosome alignment, resulting in inhibition of cytokinesis followed by apoptosis.2,3AZD 1152 inhibits tumor xenograft growthin vivo.4,5 1.Mortlock, A.A., Foote, K.M., Heron, N.M., et al.Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinaseJ. Med. Chem.50(9)2213-2224(2007) 2.Popescu, R., Heiss, E.H., Ferk, F., et al.Ikarugamycin induces DNA damage, intracellular calcium increase, p38 MAP kinase activation and apoptosis in HL-60 human promyelocytic leukemia cellsMutation Research709-71060-66(2011) 3.Moore, A.S., Blagg, J., Linardopoulos, S., et al.Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemiasLeukemia24(4)671-678(2010) 4.Wilkinson, R.W., Odedra, R., Heaton, S.P., et al.AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosisClin. Cancer. Res13(12)3682-3688(2007) 5.Yang, J., Ikezoe, T., Nishioka, C., et al.AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivoBlood110(6)2034-2040(2007)

CD532 hydrochloride is a potent inhibitor of Aurora A kinase, having an IC50 of 45 nM. It not only blocks the activity of Aurora A kinase but also facilitates the degradation of the protein MYCN. Furthermore, CD532 hydrochloride interacts directly with AURKA, inducing a significant conformational change. Its utility in cancer research has been demonstrated [1][2].

Aurora A inhibitor3 (Compound 5h) 是一种抑制Aurora-A激酶活性的化合物，IC50为0.78 μM。该化合物同时对MCF-7和MDA-MB-231细胞线表现出细胞毒性，其GI50值分别为0.12 μM和0.63 μM。

Aurora kinase-IN-1 是aurora kinase 的有效抑制剂。Aurora kinase-IN-1 上调 G1 细胞周期抑制蛋白 (包括 p21 和 p27) 以及 G1 进行性细胞周期蛋白 D1 的表达，并下调 G1-to-S 进行性细胞周期蛋白，导致细胞周期停滞在 G1 S 边界。Aurora 激酶-IN-1 还诱导细胞凋亡 (apoptosis）。Aurora 激酶-IN-1 是化疗药物的先导化合物。

GRK2 Inhibitor 2 (Compound 8h) 作为一种高效的抑制剂，对GRK2有显著的抑制活性（IC50: 19 nM），同样对Aurora-A也表现出抑制作用（IC50: 137 nM）。该化合物能增强GRK2过表达的HEK293细胞中β-AR介导的cAMP积累。此外，GRK2 Inhibitor 2适用于充血性心力衰竭（HF）的相关研究。